BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández-clotet A, Castro-poceiro J, Panés J. JAK Inhibition: The Most Promising Agents in the IBD Pipeline? CPD 2019;25:32-40. [DOI: 10.2174/1381612825666190405141410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Argollo M, Danese S. Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic. Curr Pharm Des 2019;25:5-6. [PMID: 31190642 DOI: 10.2174/138161282501190514105602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
3 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2-Inhibition: Potenzial bei der Behandlung chronisch-entzündlicher Immunerkrankungen. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34661350 DOI: 10.1111/ddg.14585_g] [Reference Citation Analysis]
4 Roda G, Dal Buono A, Argollo M, Danese S. JAK selectivity: more precision less troubles. Expert Rev Gastroenterol Hepatol 2020;14:789-96. [PMID: 32520647 DOI: 10.1080/17474124.2020.1780120] [Reference Citation Analysis]
5 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Reference Citation Analysis]
6 Oftedal BE, Wolff ASB. New era of therapy for endocrine autoimmune disorders. Scand J Immunol 2020;92:e12961. [PMID: 32853446 DOI: 10.1111/sji.12961] [Reference Citation Analysis]
7 Panés J, Vermeire S. JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. J Crohns Colitis 2020;14:S711-2. [PMID: 32737980 DOI: 10.1093/ecco-jcc/jjaa109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34580985 DOI: 10.1111/ddg.14585] [Reference Citation Analysis]
9 Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel Dis 2021;27:1674-83. [PMID: 33295611 DOI: 10.1093/ibd/izaa318] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Wang X, Gao Y, Wang L, Yang D, Bu W, Gou L, Huang J, Duan X, Pan Y, Cao S, Gao Z, Cheng C, Feng Z, Xie J, Yao R. Troxerutin Improves Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. J Agric Food Chem 2021;69:2729-44. [PMID: 33621077 DOI: 10.1021/acs.jafc.0c06755] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Garrido-Trigo A, Salas A. Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors. J Crohns Colitis 2020;14:S713-24. [PMID: 32083640 DOI: 10.1093/ecco-jcc/jjz206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
13 Yan F. Mechanistic Understanding of the Symbiotic Relationship Between the Gut Microbiota and the Host: An Avenue Toward Therapeutic Applications. Cell Mol Gastroenterol Hepatol 2020;10:853-4. [PMID: 32526162 DOI: 10.1016/j.jcmgh.2020.05.003] [Reference Citation Analysis]
14 Li Y, Altemus J, Lightner AL. Mesenchymal stem cells and acellular products attenuate murine induced colitis. Stem Cell Res Ther 2020;11:515. [PMID: 33256827 DOI: 10.1186/s13287-020-02025-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol 2021;44:39-48. [PMID: 32829958 DOI: 10.1016/j.gastrohep.2020.04.012] [Reference Citation Analysis]